Thymagen: Russian immune-support dipeptide (Glu-Trp / EW)
A tiny two-amino-acid peptide that helps regulate the immune system, derived from calf-thymus extracts; registered as a prescription drug in Russia since 1990, not approved in Western countries.
- Class
- Synthetic immunomodulatory dipeptide; thymic bioregulator
- Status
- Registered prescription pharmaceutical in Russia since 1990 (IM injection, nasal spray, topical cream; immunocorrection indication). Not approved by FDA, EMA, MHRA, Health Canada, or TGA.
- Best-supported effect
- Reduced postoperative complications and restored immune parameters in elderly surgical patients (Russian double-blind placebo-controlled study); reduced acute respiratory infection morbidity in a Russian military cohort (intranasal and SC routes). Evidence is concentrated in the Khavinson program and Russian clinical network; no independent Western replication identified.
- Main caveat
- All human evidence originates from the Khavinson research program and Russian clinical network. Independent Western replication is essentially absent. Russian pharmaceutical registration is not equivalent to FDA or EMA approval. No Western-standard RCTs are indexed in major databases.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Thymagen (also marketed as Thymogen) is a synthetic two-amino-acid peptide — glutamic acid linked to tryptophan (Glu-Trp; single-letter EW) — that has been registered as a prescription immune-support pharmaceutical in Russia since 1990. It was identified by Vladimir Khavinson and Vladimir Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as one of the active components of Thymalin, a calf-thymus peptide extract used in Soviet medicine, and then re-synthesized as a chemically defined drug. Both residues are the natural L-form: the mirror-image dipeptide (D-Glu-D-Trp, marketed in Russia as Thymodepressin) does the opposite — it suppresses the immune system rather than stimulating it — which is unusual in peptide pharmacology and makes stereochemical identity central to anything Thymagen does (Deigin and colleagues, International Journal of Molecular Sciences, 2024). Thymagen is not approved by the FDA, EMA, MHRA, Health Canada, or TGA, and the great majority of its evidence base comes from a single Russian research program.
History
Khavinson and Morozov's group began work on a heterogeneous calf-thymus extract called Thymalin in the 1970s as part of a long-running Soviet program in "peptide bioregulators" — short peptides hypothesized to support tissue-specific function and counter age-related decline. In the 1980s the group fractionated Thymalin by reverse-phase HPLC and identified L-Glu-L-Trp as a principal immunostimulatory component, alongside a second active dipeptide L-Lys-L-Glu (KE, later marketed as Vilon). The synthetic L-Glu-L-Trp was registered with the Russian Ministry of Health in 1990 as Thymogen in three formulations: intramuscular injection, intranasal spray, and topical cream (Deigin and colleagues, International Journal of Molecular Sciences, 2024). The chiral counterpart D-Glu-D-Trp was later developed as Thymodepressin and registered separately as an immunosuppressant. Thymagen sits in the same Khavinson "bioregulator" family as Epithalon (/card/pep-00008) and Pancragen (/card/pep-10935), with the same caveat: independent Western replication is essentially absent.
What it does
Thymagen is described as an immune-restoration drug — used in Russia to help bring depressed T-cell function back toward normal in older adults, post-surgical patients, and people with chronic infections. The proposed effects across published research are: pushing T-lymphocyte populations toward more mature, functional states; dampening over-active inflammatory signaling from monocytes and macrophages; supporting neutrophil chemotaxis and phagocytosis; and reducing the rate of acute respiratory infections when given as a nasal spray. The L-form stimulates these processes; the D-enantiomer reverses them, which is one of the more concrete pieces of evidence that the molecule is acting on a stereospecific target rather than as a generic amino-acid supplement (Deigin and colleagues, International Journal of Molecular Sciences, 2024).
Evidence
- Human: Russian clinical literature only; no Western RCTs are indexed in major databases. A clinical study in type 1 diabetes patients with secondary immunodeficiency reported activation of T-lymphocyte differentiation with clinical improvement in 94.4% and laboratory improvement in 83.3% of patients (Zhuk and Galenok, Terapevticheskii Arkhiv, 1996). A military-cohort study found that intranasal and subcutaneous Thymogen reduced the incidence, severity, and duration of acute respiratory viral infections in a training unit (Furgal and colleagues, Voenno-Meditsinskii Zhurnal, 1993). A double-blind placebo-controlled study in elderly post-surgical patients reported restored immune parameters and reduced postoperative complications; this study is described in the Russian-language literature but is not individually indexed in major Western databases.
- Animal: A 12-month treatment study in 76 female rats reported that L-Glu-L-Trp (5 µg per rat, five times weekly) extended the maximum lifespan of the top 10% of animals to 1048 ± 21.1 days vs. 949 ± 16.1 days in controls (p < 0.001), reduced total spontaneous tumor incidence 1.5-fold, malignant tumors 1.7-fold, and hematopoietic malignancies (leukemias and lymphomas) 3.4-fold (Anisimov, Khavinson and Morozov, Biogerontology, 2000). No independent replication outside the Khavinson program has been identified.
- In vitro: In the THP-1 monocyte/macrophage cell line, Thymogen (alongside other Khavinson peptides) inhibited LPS-induced expression of TNF and IL-6, reduced monocyte adhesion to activated endothelial cells, and was characterized as a natural inducer of TNF tolerance (Caputi and colleagues, International Journal of Molecular Sciences, 2022). Bioinformatic and cell-model analyses of the EW dipeptide in a COVID-19 inflammation context reported reduced expression of ACE2 and CYSLTR1 and reduction of IL-1β, IL-6, and TNF-α synthesis by approximately 1.4- to 6.0-fold in LPS-stimulated peripheral blood mononuclear cells (Khavinson and colleagues, International Journal of Molecular Sciences, 2023; Khavinson and colleagues, Molecules, 2020).
Myths and misconceptions
- "Russian registration since 1990 means Western-equivalent regulatory validation." It doesn't. Russian pharmaceutical registration reflects an internal regulatory verdict on Russian-generated data. It is not equivalent to FDA, EMA, MHRA, Health Canada, or TGA approval, which have different evidence requirements that have not been satisfied for this compound.
- "Vladimir Khavinson won the Nobel Prize for the peptide bioregulator work that produced Thymagen." He did not. The attribution circulates online but is inaccurate.
- "Research-chemical Thymagen is biologically equivalent to the Russian pharmaceutical." Stereochemical purity matters here more than for most peptides: the L-form is immunostimulatory and the D-form (Thymodepressin) is immunosuppressive (Deigin and colleagues, International Journal of Molecular Sciences, 2024). Identity, purity, and sterility of non-pharmaceutical research-chemical supply cannot be assumed equivalent to a Russian pharmaceutical-grade product.
- "It's only two amino acids, so it must be harmless." Molecular size doesn't establish safety. The dipeptide is reported to modulate immune-cell function and inflammatory gene expression — exactly the kind of activity that requires careful evaluation, particularly in autoimmune disease or in patients with subclinical malignancy.
Mechanism
The proposed mechanisms span several pathways, with different levels of independent confirmation.
T-cell differentiation support. Thymagen is reported to activate T-cell differentiation and enhance recognition of peptide–MHC complexes, supporting thymic immune function that declines with age (Deigin and colleagues, International Journal of Molecular Sciences, 2024; Anisimov and colleagues, Biogerontology, 2000).
Cyclic-nucleotide modulation. The dipeptide is proposed to inhibit phosphodiesterase activity, raising intracellular cAMP and cGMP and altering immune-cell responsiveness. This pathway is described in the Khavinson literature and has not been independently re-derived outside that program.
Anti-inflammatory cytokine regulation. In THP-1 monocytes under LPS challenge, Thymogen inhibited TNF and IL-6 expression and reduced monocyte adhesion to LPS-activated HUVEC endothelial cells, behaving as an inducer of TNF tolerance (Caputi and colleagues, International Journal of Molecular Sciences, 2022). In a COVID-19-focused analysis, the EW peptide reduced ACE2 and CYSLTR1 expression and lowered IL-1β, IL-6, and TNF-α synthesis 1.4- to 6.0-fold in LPS-stimulated PBMCs (Khavinson and colleagues, International Journal of Molecular Sciences, 2023).
Proposed epigenetic mechanism. The Khavinson group has used molecular modeling to argue that L-Glu-L-Trp binds directly to DNA regulatory regions and histone H1/H3 proteins, altering chromatin accessibility for immune-related gene clusters (Khavinson and colleagues, Molecules, 2020). This hypothesis remains internal to the Khavinson program; no independent structural-biology or biochemistry replication has been identified.
Stereochemical evidence for a specific target. The L-enantiomer is immunostimulatory; the D-enantiomer (Thymodepressin) reverses these effects (Deigin and colleagues, International Journal of Molecular Sciences, 2024). Reciprocal chiral activity is indirect but real evidence for a stereospecific molecular interaction, even though the receptor or binding partner has not been identified by independent methods.
The two-letter sequence stored on this card (EW) is a free, unmodified L-glutamyl-L-tryptophan dipeptide; the chirality at both residues is what matters most for the biology and is not visible from single-letter code alone.
Safety signals
Drawn from Russian clinical literature and from class-level considerations described in published sources. Independent Western pharmacovigilance has not been conducted.
- Generally well tolerated across Russian clinical studies and over three decades of registered pharmaceutical use; no significant adverse effects reported in the available Russian literature. This real-world record has not been replicated under Western pharmacovigilance standards.
- Rare individual hypersensitivity reactions described as possible; frequency not quantified to Western standards.
- Stereochemical risk specific to this dipeptide: D-Glu-D-Trp has opposite, immunosuppressive activity (Deigin and colleagues, International Journal of Molecular Sciences, 2024). Identity and stereochemical purity of non-pharmaceutical supply cannot be assumed.
- Pregnancy and breastfeeding: no adequate reproductive toxicology data; use not recommended in available source guidance.
- Active autoimmune disease: immunostimulation in this context is a theoretical concern; clinician evaluation needed.
- Active or recent hematologic malignancy: immune-cell stimulation is a class-level concern in lymphoid malignancy contexts.
- Formal pharmacokinetics (absorption, distribution, metabolism, clearance) have not been characterized in humans to Western standards.
- Long-term cumulative-course safety has not been independently evaluated.
Regulatory status
- Russia: Registered prescription pharmaceutical since 1990 in three formulations — intramuscular injection, intranasal spray, and topical cream — for immunocorrection indications. Russian Ministry of Health registration certificate №P N002408/01, reissued 2009 (Deigin and colleagues, International Journal of Molecular Sciences, 2024).
- United States (FDA): Not approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A pharmacy compounding. Sold through research-chemical suppliers not authorized for human use.
- European Union (EMA): Not approved.
- United Kingdom (MHRA): Not approved.
- Canada (Health Canada): Not approved.
- Australia (TGA): Not approved.
- WADA: Not specifically named on the WADA Prohibited List. As a parenteral substance without governmental health-authority approval in most WADA-code jurisdictions, the S0 catch-all category is likely applicable for athletes outside Russia; status not independently refreshed in this card.
No Western-registry clinical trials for Thymagen, Thymogen, or L-Glu-L-Trp dipeptide were identified in this authoring pass; all identified human-study evidence originates from the Russian research context.
Open questions
- Independent Western replication. Core efficacy and mechanistic claims have not been reproduced by Western or otherwise unaffiliated laboratories under modern controlled-trial methodology. This is the single largest gap.
- Human pharmacokinetics. Absorption (especially across nasal mucosa), distribution, metabolism, and clearance have not been characterized to Western standards. Whether an unmodified dipeptide reaches target tissues at bioactive concentrations by any route is unknown.
- Primary receptor or binding partner. The proposed direct DNA and histone binding by a dipeptide has not been independently confirmed by structural biology. The molecular target responsible for the L-vs-D enantiomer activity difference has not been identified by independent biochemistry.
- Human translation of the rat lifespan and anti-tumor findings. The Anisimov 2000 rat result is from a single program and has no human-endpoint counterpart.
- Cancer-promotion risk in susceptible populations. Immune stimulation in patients with subclinical malignancy is a class-level concern that available evidence does not adequately address.
- Stereochemical purity verification in research-chemical supply. Given reciprocal L/D activity, the lack of identity and purity testing for non-pharmaceutical supply is a real biological risk, not a theoretical one.
Related peptides
- Epithalon (AEDG) — pineal-derived tetrapeptide from the same Khavinson program, marketed as a longevity candidate.
- Pancragen (KEDP) — pancreatic-tissue Khavinson tetrapeptide; the synthetic counterpart to the Suprefort extract.
- Thymalin — the heterogeneous calf-thymus extract from which L-Glu-L-Trp was originally isolated (no platform card identified).
- Vilon (Lys-Glu, KE) — the other principal immunostimulatory dipeptide isolated from Thymalin (no platform card identified).
- Thymodepressin (D-Glu-D-Trp) — the chiral counterpart with opposite, immunosuppressive activity (no platform card identified).
- Thymosin alpha-1 — independently developed thymic immunomodulator outside the Khavinson program (no platform card identified).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the dramatic difference between the two mirror forms of Thymagen prove it is locking onto a dedicated immune receptor rather than just being a nutrient?
If Thymagen has its own receptor, scientists could find that receptor and design much more powerful drugs to tune the immune system up or down, opening new treatments for infections, autoimmunity, and aging-related immune decline.
In this tiny two-amino-acid drug, does one part do the binding and the other just hold it in the right shape?
Knowing which part of a dipeptide drug matters most lets chemists build a more stable version that might survive digestion and work as an oral pill rather than an injection or nasal spray.
Could the mirror-image form of this immune-boosting dipeptide safely calm overactive immune systems in diseases like rheumatoid arthritis?
Drugs that suppress the immune system in autoimmune disease often cause serious infections and organ damage. A dipeptide based on a natural immune signal might achieve the same suppression with far fewer side effects, helping patients with conditions like lupus or inflammatory bowel disease.
Does this peptide specifically target the T-cell part of the immune system, or does it affect all immune cells equally?
A drug that specifically boosts T cells without broadly activating the immune system could be used alongside vaccines in elderly or immunocompromised patients to make vaccines work better, without the risk of dangerous inflammatory side effects from non-selective immune stimulation.
Can this tiny peptide, originally found in thymus tissue, help an elderly person's thymus produce new immune cells again?
As people age, their immune system runs out of fresh cells, leaving them vulnerable to new infections and less able to benefit from vaccines. A simple, stable dipeptide that reactivates the thymus could help older adults maintain stronger immunity, with far fewer side effects than current immune-boosting treatments.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8608492612838745 | openfold3-mlx |
| ranking score | 0.9081118106842041 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.418 | global PDE — lower = better |
| disorder | 0.093 | fraction disordered |
| chain pair ipTM (A, B) | 0.861 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 78s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10919,
sequence = {EW},
target = {immune},
author = {peptidemodel},
year = {2026},
status = {computed}
}